

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal


Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]

Final Stakeholder list

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
CSL Behring (garadacimab)	 All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Action for Children	Board of Community Health Councils in
Allergy UK	Wales
Anaphylaxis UK	British National Formulary
 Asthma and Lung UK 	Care Quality Commission
Genetic Alliance UK	 Cell and Gene Therapy Catapult
HAE UK	Department of Health, Social Services
Immunodeficiency UK	and Public Safety for Northern Ireland
Jnetics	Healthcare Improvement Scotland
NARA - The Breathing Charity	Hospital Information Services –
National Children's Bureau	Jehovah's Witnesses
South Asian Health Foundation	Medicines and Healthcare products
Specialised Healthcare Alliance	Regulatory Agency
UK Primary Immune-deficiency	National Association of Primary Care
Patient Support Charity (UKPIPS)	 National Pharmacy Association NHS Alliance
Healthcare professional groups	 NHS Alliance NHS Confederation
 Association for Respiratory 	 Scottish Medicines Consortium
Technology and Physiology	 Welsh Government
 Association of Genetic Nurses & 	 Weish Government Weish Health Specialised Services
Counsellors	Committee
Association of Paediatric Emergency	Committee
Medicine	Comparator companies
British Geriatrics Society	 BioCryst Pharmaceuticals (berotralstat)
British Paediatric Allergy, Immunity	CSL Behring (Berinert)
and Infection Group (BPAIIG)	Maxwellia (tranexamic acid)
British Paediatric Respiratory Society	• Mylan (tranexamic acid)
British Skin Foundation	Pharming Group N.V (Ruconest)
British Society for Allergy & Clinical	Rivopharm (tranexamic acid)
Immunology	Sovereign Medical (tranexamic acid)
British Society for Gene and Cell	Takeda (Cinryze, lanadelumab)
Therapy	• Tillomed Laboratories (tranexamic acid)
British Society for Genetic Medicine	. , , ,

Final stakeholder list for the evaluation of garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394] Issue date: September 2024

© National Institute for Health and Care Excellence 2024. All rights reserved.




Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Society for Haematology British Society for Immunology British Thoracic Society BSI Clinical Immunology Professional Network (BSI-CIPN) ILD-IN: Interstitial Lung Diseases Interdisciplinary Network Immunology and Allergy Nurses Group National Heart and Lung Institute Neonatal and Paediatric Pharmacists Group Primary Care Respiratory Society UK Royal College of General Practitioners Royal College of Paediatrics & Child Health Royal College of Paediatrics & Child Health Royal College of Physicians Royal College of Physicians Royal Society of Medicine Royal Society of Medicine Royal Society of Medicine - Allergy and Immunology Section UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders Others Department of Health and Social Care NHS England 	Submit of appeal) Relevant research groups Asthma, Allergy and Inflammation Research Trust British Association for Lung Research Cochrane Airways Group Cochrane UK David Hide Asthma and Allergy Research Centre Genomics England MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Final stakeholder list for the evaluation of garadacimab for preventing recurrent attacks of hereditary
angioedema in people 12 years and over [ID6394]
Issue date: September 2024© National Institute for Health and Care Excellence 2024. All rights reserved.2 of 3



Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Consultee or commentator stakeholders are provisional until a CA&U form is signed at appraisal stage.